Assessment of change in antimicrobial susceptibility pattern of bacteria causing orthopaedic infections by sequential sampling: A prospective cohort study.

Background: Management of Orthopaedic wound infections often depend on isolation of bacteria species (spp.) and its subsequent antimicrobial susceptibility testing (AST). However, the susceptibility to antibiotics may change over time in the same bacterial spp. particularly after initiation of antibiotic therapy. Repeating AST through sequential sampling can be used for the early detection of changes in antimicrobial susceptibility pattern. However, the recommendations about the optimal frequency of repeat AST for same bacterial spp. isolates from same patient to detect the changes in susceptibility patterns are still not established. Furthermore, no prospective research is available to address the crucial issue. Thus, we aimed this study to evaluate the need of repeat AST through sequential samples from the same site. Methods: AST was performed on same bacterial spp. isolates from three sequential samples using Kirby-Bauer disc diffusion method. Considering day 1 as control/baseline, changes in antimicrobial susceptibility pattern was interpreted on two sequential instances (on day 3 and day5). Changes were categorized into favorable & unfavorable and major & minor change categories. Results: The overall change in antimicrobial susceptibility pattern was 28 % on instance 1(on day3) and 36.1 % at instance 2 (on day 5). Susceptible to resistance phenotypic change was 14.9 % at instance 1 and 9.2 % at instance 2.A higher percentage change per case in antimicrobial susceptibility pattern was observed at instance 2. Predominant changes were towards the direction of favorable antimicrobial susceptibility pattern. Conclusion: The risk of change in antimicrobial susceptibility potential was over 10 % at both the instances. Furthermore, it was higher at instance 2 i.e., at day5, therefore a repeat sequential antimicrobial susceptibility testing would be recommended at later instance.

Neurodevelopmental outcomes following bevacizumab treatment for retinopathy of prematurity: a systematic review and meta-analysis.

OBJECTIVE: To systematically review the studies exploring the association between bevacizumab and neurodevelopmental outcomes. METHODS: Embase, Medline, CINAHL, and Cochrane Library databases were searched for studies examining neurodevelopmental outcomes of preterm infants treated with bevacizumab compared to laser ablation or cryotherapy for severe retinopathy of prematurity (ROP). RESULTS: Thirteen studies (clinical trial = 1; cohort studies = 12) were included. Random-effects model meta-analysis showed significant increased odds of cognitive impairment associated with bevacizumab treatment on both unadjusted (unadjusted odds ratio (OR) 1.61; 95% confidence interval (CI) 1.12, 2.30) and adjusted analyses (adjusted OR 1.90; 95% CI 1.22, 2.97). Infants treated with bevacizumab for severe ROP had significantly lower Bayley-III cognitive (mean difference (MD) -1.66; 95% CI -3.21, -0.12), and language composite scores (MD -5.50; 95% CI -8.24, -2.76) compared to infants treated with laser ablation or cryotherapy. CONCLUSION: Bevacizumab treatment for severe ROP is associated with increased risk of cognitive impairment and lower cognitive and language scores in preterm infants.

Correlation of self-reported sleep duration with working memory of adolescents.

CONTEXT: With the increasing use of electronic devices and social media, the duration of sleep has consistently reduced in adolescents. Sleep restriction eventually leads to cognitive performance declines. Poor sleep and working memory difficulties are both associated with learning difficulties leading to poor academic performance. AIMS: We postulated that decreased sleep duration decreases the working memory of adolescents and eventually their academic performance. SETTINGS AND DESIGN: Cross-sectional Study. METHODS AND MATERIAL: The study was conducted on 114 school students; 62 boys and 52 girls (age 13.8 ± 0.91 and 13.65 ± 0.88 years, respectively). Sleep was monitored by self-reported diary. Working memory was tested by the n-back task. The students were given 1-back and 2-back visual tasks in two blocks and accuracy of each of the tests was calculated. STATISTICAL ANALYSIS USED: Prism software was used and Mann-Whitney-U test and Spearman Correlation tests were employed. RESULTS: Sleep duration range was 4.15-12 hours with a mean of 7.63 ± 1.35 hours. The sleep duration in males and females, respectively was 6.94 ± 0.94 hrs. and 8.5 ± 1.31 hrs.; significant (p = 0.0001). The total n-back score accuracy (1-back and 2-back) was 52.11 ± 17.32% in males and 52.24 ± 17.40% in females (p = 0.976). Spearman Correlation between sleep-duration and total n-back score was not found to be statistically significant (p = 0.611). However, the correlation of total n-back score with academic performance was statistically significant. CONCLUSIONS: The working memory was not statistically different in males and females, and was not significantly correlated with sleep duration, though it was significantly associated with the academic performance.

Pro-Atherogenic Inflammatory Mediators in Inflammatory Bowel Disease Patients Increase the Risk of Thrombosis, Coronary Artery Disease, and Myocardial Infarction: A Scientific Dilemma.

Inflammatory bowel disease (IBD), comprising ulcerative colitis and Crohn's disease, is characterized by widespread inflammation of the gastrointestinal tract with systemic manifestations. Inflammation is one of the driving forces for the pathogenesis of atherosclerosis and its dreaded complications like myocardial infarction (MI). Yet, the association between IBD and myocardial infarction has not been thoroughly established. Myocardial infarction in IBD patients was predominantly seen in young women during the active disease process. At the same time, elevated levels of C-reactive protein and other pro-inflammatory markers were observed in both IBD and atherosclerosis. Increasing evidence suggests inflammation inhibits fibrinolysis, expresses procoagulants, and suppresses anticoagulants promoting thrombosis formation. Moreover, the alteration of gut microbiota impacts the pathogenesis of inflammation and predisposes one to ischemic heart disease. Accordingly, all IBD patients should be screened and counseled on lifestyle modifications for the traditional risk factors of atherosclerosis. Future researchers should consider conducting more clinical trials on anti-inflammatory medication targeting atherosclerosis and therapeutics, while targeting the gut microbiota to reverse the inflammatory atherosclerotic process.